Composition & Public Health Rationale

  • Hexavalent vaccines combine protection against six pathogens into a single injection: Diphtheria (D), Tetanus (T), Pertussis (wP or aP), Hepatitis B (HepB), Haemophilus influenzae type b (Hib), and Poliomyelitis (Inactivated Polio Vaccine, IPV).
  • The Challenge in India's UIP: Under the current Universal Immunization Programme (UIP), an infant at 6 and 14 weeks receives up to 3 injections per visit (Pentavalent IM, PCV IM, and fractional IPV intradermally) plus oral Rotavirus and OPV drops.
  • Benefits of Hexavalent Formulation:
    • Reduces total infant injections from 9 injections down to 3 injections during the primary series (at 6, 10, and 14 weeks).
    • Eliminates intradermal fractional IPV (fIPV) administration errors (difficult intradermal technique, bleb failures, and vaccine spillage in peripheral sub-centers).
    • Reduces cold-chain volume requirement by approximately $30–40\%$ by eliminating separate IPV and Pentavalent vials.
    • Improves national immunization completion and reduces dropout rates between dose 1 and dose 3 ($>12\%$ drop-off observed in rural districts).

Comparison Of Hexavalent Formulations Available In India

ParameterFully Liquid DTwP-HepB-Hib-IPV (e.g., EasySix, Shan6)Fully Liquid DTaP-HepB-Hib-IPV (e.g., Hexaxim, Infanrix Hexa)
Pertussis ComponentWhole-Cell Pertussis (wP) (chemically inactivated whole B. pertussis)Acellular Pertussis (aP) (purified pertussis toxoid, FHA, pertactin $\pm$ fimbriae)
ManufacturersPanacea Biotec (EasySix), Sanofi/Shantha (Shan6), SIISanofi (Hexaxim), GSK (Infanrix Hexa)
Immunogenicity & DurabilitySuperior, longer-lasting immunity; stimulates robust mucosal and herd immunity; preferred for public health in endemic LMICsHigh early seroprotection; faster waning of pertussis antibody titers over 3–5 years
ReactogenicityHigher rates of transient fever, crying, and local pain ($20–40\%$)Significantly lower rates of fever, local erythema, and irritability ($<10\%$)
PreparationFully liquid ready-to-use; zero reconstitution requiredFully liquid (Hexaxim) or lyophilized Hib/IPV cake
RecommendationPreferred by IAP ACVIP and NTAGI for programmatic UIP transitionPreferred in private practice for parents prioritizing minimal post-shot fever

Current UIP vs. Proposed Hexavalent Schedule

flowchart TD
    subgraph Current UIP Protocol (Multiple Injections)
        A["6 & 14 Weeks Infant Visit"] --> B1["IM Thigh 1: Pentavalent (DTwP-HepB-Hib)"]
        A --> B2["IM Thigh 2: Pneumococcal Conjugate (PCV)"]
        A --> B3["Intradermal Deltoid: Fractional IPV (fIPV 0.1 mL)"]
        A --> B4["Oral: Rotavirus drops + bOPV drops"]
        style A fill:#fff3e0,stroke:#e65100
    end

    subgraph Proposed Hexavalent UIP Protocol (Streamlined)
        C["6 & 14 Weeks Infant Visit"] --> D1["<b>IM Thigh 1: Fully Liquid DTwP-HepB-Hib-IPV</b><br>(Single 0.5 mL injection)"]
        C --> D2["<b>IM Thigh 2: Pneumococcal Conjugate (PCV)</b>"]
        C --> D3["Oral: Rotavirus drops"]
        style C fill:#e8f5e9,stroke:#2e7d32
    end

Clinical Trial Evidence & Immunogenicity

  1. Indian Phase 3 Trials (Pivotal Non-Inferiority Studies):
    • Evaluated fully liquid DTwP-HepB-Hib-IPV (EasySix / Shan6) against separately administered commercial pentavalent plus standalone IPV.
    • Seroprotection Rates: $>98\%$ for Diphtheria and Tetanus antitoxin; $>96\%$ for anti-HBs ($\ge 10\text{ mIU/mL}$); $>95\%$ for anti-PRP (Hib); $>98\%$ seroconversion for Poliovirus types 1, 2, and 3.
    • Booster Response at 15–18 Months: Vigorous anamnestic response with persistent antibodies demonstrable at 4 to 5 years of age.
  2. Safety Profile:
    • No reports of hypotonic-hyporesponsive episodes (HHE), encephalopathy, or anaphylaxis in large randomized trials ($n>2,000$).
    • Adverse events were predominantly mild, self-limiting local swelling and pyrexia responding promptly to paracetamol.

National Status & Implementation Barriers

  • NTAGI Deliberations: The National Technical Advisory Group on Immunization (NTAGI) has formally reviewed the hexavalent platform. Key considerations include:
    1. Cost differential: Procurement cost of hexavalent vaccines remains higher than pentavalent alone, though total operational savings (reduced syringes, fewer cold-chain trips, diminished waste) partially offset product cost.
    2. Domestic production security: Approval of indigenous manufacturers (Panacea Biotec, Serum Institute of India) ensures sovereign supply chain security without relying on multinational tenders.
    3. Universal IPV coverage: Solves the challenge of global IPV supply constraints by embedding low-dose inactivated polio strains into existing multi-antigen products.
  • IAP ACVIP Position: Recommends fully liquid DTwP-based hexavalent vaccines as the preferred standard for primary series at 6, 10, and 14 weeks in outpatient pediatrics.